Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TLR9-based immunotherapy for allergic disease.

Tomoko Hayashi1, Eyal Raz

  • 1Department of Medicine, University of California San Diego, La Jolla CA, 92093, USA.

The American Journal of Medicine
|September 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of community pharmacy-based telephone follow-up on treatment completion in cancer patients receiving adjuvant chemotherapy: A retrospective observational study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.

Vaccine·2026
Same author

Structure-Activity Relationship Studies in Substituted Oxadiazoles as Inducers of Extracellular Vesicles.

Journal of medicinal chemistry·2026
Same author

Application of a small molecule calcium influx inducer as a vaccine adjuvant: enhancing Th2-biased immune responses.

Frontiers in immunology·2026
Same author

Multi-omics profiling reveals microenvironmental remodeling as a key driver of house dust mite-induced lung cancer progression.

Neoplasia (New York, N.Y.)·2026
Same author

A novel calcium influx inducer and a TLR7 agonist are synergistic co-adjuvants that enhance cross-reactive immunity against influenza in young and aged mice.

Vaccine·2026

Toll-like receptor (TLR) 9-based therapies show promise for treating allergic diseases. These strategies, including immunomodulation and vaccination, offer potential advantages over current treatments for conditions like asthma.

Area of Science:

  • Immunology
  • Allergy Research
  • Pharmacology

Background:

  • Allergic disorders represent a significant health burden.
  • Current treatments for allergies have limitations.
  • Toll-like receptor (TLR) 9 agonists have emerged as a potential therapeutic avenue.

Purpose of the Study:

  • To review the efficacy of two distinct Toll-like receptor (TLR) 9-based therapeutic strategies.
  • To evaluate TLR9-based immunomodulation and TLR9-based vaccination for allergic diseases.
  • To assess the potential of TLR9 ligands (TLR9-L) in revolutionizing allergy treatment.

Main Methods:

  • Review of experimental data on TLR9-based immunotherapy in animal models of allergic disorders.
  • Analysis of immunomodulatory effects of TLR9 ligands, including indoleamine 2.3-dioxygenase induction.

Related Experiment Videos

  • Evaluation of TLR9-based vaccination for allergen-specific immunotherapy.
  • Assessment of current clinical trial data for TLR9-based immunotherapy.

    • Main Results:

    • TLR9-based immunomodulation transiently prevents and reverses allergic inflammation in models of asthma, rhinitis, and conjunctivitis.
    • TLR9-L induces indoleamine 2.3-dioxygenase, mediating anti-inflammatory effects.
    • TLR9-based vaccination provides long-term inhibition of allergen-specific hypersensitivities.
    • Clinical trials indicate high efficacy and safety of TLR9-based immunotherapy compared to conventional desensitization.

    Conclusions:

    • TLR9-based immunomodulation offers a broad therapeutic potential independent of specific allergens.
    • TLR9-based vaccination provides allergen-specific, long-term allergy treatment.
    • TLR9-L based therapies may represent a revolutionary approach to managing allergic diseases.